Management of toxicities from antibody – drug conjugates in breast cancer - Summary - MDSpire

Management of toxicities from antibody – drug conjugates in breast cancer

  • By

  • Ajay Gogia

  • May 29, 2026

  • 0 min

Share

Objective:

To synthesize clinical-trial, post-marketing, and real-world data to create a unified, organ-system–based framework for anticipating, preventing, and managing toxicities associated with antibody-drug conjugates (ADCs) in breast cancer treatment.

Key Findings:
  • Remove unsupported claims about practical algorithms.
Interpretation:

Remove unsupported conclusions about implications.

Limitations:
  • Make limitations more concise.
Conclusion:

Revise to remove unsupported claims about addressing practice gaps.

Original Source(s)

Management of toxicities from antibody – drug conjugates in breast cancer

  • by Ajay Gogia

  • May 29, 2026

Related Content

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases